Biozzi ABH mice develop a reproducible, relapsing-remitting form of experimental autoimmune encephalomyelitis (EAE) that becomes secondary progressive with disease duration. The relapses observed are T-cell dependent and can be inhibited by immune tolerance induction. In contrast the progressive neurodegeneration is T cell-independent and continues despite the re-induction of immune tolerance. Here we present a practical guide to EAE induction in the ABH mouse and approaches used to control relapses such that both autoimmune-independent and autoimmune-dependent mechanisms of neurodegeneration can be explored. Disease-related weight changes are associated with blood-brain barrier dysfunction and clinical disease. A new method for detecting neurodegeneration is described along with new experimental details that will aid in the undertaking of studies in EAE in mice, with particularly emphasis on ABH mice.
To most of you reading the blog, you don’t care much about animal work, but you do care about finding treatments.
Animals are one way to do this as we showed with the phenytoin in optic neuritis study that has implications for progressive MSers.
However, it is a research blog, and it is our research blog, so we need to engage people in what we do.
Biozzi Mice is a strain of mice that we became custodians of and showed that is a mouse strain that is highly susceptible to relapsing autoimmunity and also has secondary progressive disease. The were bred by a Brazilian (Guido Biozzi) working in Paris, France to study the genetic regulation of the antibody response and the ABH strain made high levels of antibody (AB=antibody, H = High). This is one of the best mouse strains for drug hunting because disease is reproducible. However we have to remember it is just one individual
The ARRIVE guidelines (CLICK) is a guideline of how to report animal studies to increase transparency.
Much animal work is in need of this transparency, because animal studies consistently fail to translate anything useful to humans.
I am sorry to say some of it would not translate into animal benefit because the experiments lack enough internal quality control.
Whilst I will take stick for staying this in a public forum, the results are out there for everyone to see and it is supposed to be a constructive rather than a destructive comment.
It is written in stone in Europe that people using animals need to embrace the principles of 3Rs of animal work. This is not readin, rightin and rithmatic or reuse reduce and recycle but Refinement (of protocols to minimise suffering), Reduction (In the number of animals used) and Replacement(Using non animal alternatives).
If we do not aim to work to high standards,in the not too distant future, ethical review committees make take the view that the ends do not justify the means.
This study was published years ago as soon as the ARRIVE guidelines came out but was invisible as MSARDS failed to be seen on Pubmed and so was invisible until last week.
CoI This produced by TeamG